Central Trust Company’s Lineage Cell Therapeutics LCTX Stock Holding History

Central Trust Company’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-29	Closed	-$43	–	1433
2024 Q1	$43	Hold	29	–	–	﹤0.01%	1366
2023 Q4	$32	Hold	29	–	–	﹤0.01%	1376
2023 Q3	$35	Hold	29	–	–	﹤0.01%	1353
2023 Q2	$41	Hold	29	–	–	﹤0.01%	1226
2023 Q1	$44	Hold	29	–	–	﹤0.01%	1260
2022 Q4	$34	Hold	29	–	–	﹤0.01%	1243
2022 Q3	$0	Hold	29	–	–	﹤0.01%	1367
2022 Q2	$0	Hold	29	–	–	﹤0.01%	1414
2022 Q1	$0	Hold	29	–	–	﹤0.01%	1429
2021 Q4	$0	Hold	29	–	–	﹤0.01%	1308
2021 Q3	$0	Hold	29	–	–	﹤0.01%	1270
2021 Q2	$0	Hold	29	–	–	﹤0.01%	1224
2021 Q1	$0	Hold	29	–	–	﹤0.01%	1126
2020 Q4	$0	Hold	29	–	–	﹤0.01%	1087
2020 Q3	$0	Hold	29	–	–	﹤0.01%	1087
2020 Q2	$0	Hold	29	–	–	﹤0.01%	1108
2020 Q1	$0	Hold	29	–	–	﹤0.01%	1183
2019 Q4	$0	Hold	29	–	–	﹤0.01%	1194
2019 Q3	$0	Hold	29	–	–	﹤0.01%	1170
2019 Q2	$0	Hold	29	–	–	﹤0.01%	1158
2019 Q1	$0	Buy	+29	New	+$36	﹤0.01%	1126

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Central Trust Company's LCTX Position: Q2 2024 in Review

Central Trust Company sold out of Lineage Cell Therapeutics (LCTX) in Q2 2024, closing a stake of 29 shares — an estimated $43 sold.

Central Trust Company first reported a position in LCTX in Q1 2019 and held it in 21 quarters. The position peaked at $44 in Q1 2023. 113 funds tracked by Wall St. Rank hold LCTX as of Q2 2024.

Central Trust Company reported no remaining Lineage Cell Therapeutics position as of Q2 2024 after selling out during the quarter.
Central Trust Company sold 29 Lineage Cell Therapeutics shares in Q2 2024, an estimated $43.
Central Trust Company first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 21 quarters.
Central Trust Company's Lineage Cell Therapeutics position peaked at $44 in Q1 2023.
113 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2024.

Based on Central Trust Company's 13F filing for Q2 2024, filed 5 Aug 2024.